Recent studies suggest that the action of plateletactivating factor (PAF), a potent phospholipid modulator of allergic and inflammatory reactions, is diverse and functions as a modulator of a variety of physiological and pathological events in many cell types and tissues. Its role (if any) in modulating the proliferation, transformation and/or differentiation of epithelial colonic cells, however, is not known. In this study, we showed that PAF is biologically active in epithelial-derived human colon carcinoma cells with different phenotypic properties. These cells expressed the PAF receptor. PAF activated three prominent mitogen-activated protein kinase modules (ERK, p38MAPK and Jun N-terminal kinases) in these cells, inhibited proliferation and induced differentiation (measured by the induction of Waf1/p21 and the induction of the differentiation-related marker CEA). The net effect of PAF treatment was the suppression of malignant cell behavior (measured by anchorage-independent growth and cellular invasion). It is concluded that PAF is a modulator of proliferation and differentiation in human epithelialderived colon carcinoma cells.
Platelet-activating factor (PAF) is a naturally occurring phospholipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) cytokine and is well known as a potent mediator of allergic and inflammatory reactions (Prescott et al., 2000) and a potent regulator of proliferation and differentiation of immune cells (Stoll et al., 1991; Saito et al., 1992; Smith and Shearer, 1994) . Recent studies suggest that the action of this potent lipid mediator is involved in a variety of physiological and pathological events in many cell types and tissues. In neuronal cells, the glutamate receptor-induced cell death is mediated by the action of PAF on mitogen-activated protein (MAP) kinases (Mukherjee et al., 1999) and PAF expression enhances cold-induced brain injury (Tokutomi et al., 2001) . PAF stimulation of MAP kinases is implicated in the regulation of proliferation and differentiation of noninflammatory cells (Honda et al., 1994; Shimada et al., 1998) , and stimulates the proliferation of epidermal cells in a MAP kinase and epidermal growth factor receptor-dependent manner (Marques et al., 2002) . In addition, PAF has been reported to regulate mucin secretion in colonic epithelial cells (Sperber et al., 1998) , remodeling of the extracellular matrix in corneal epithelial cells (Bazan and Tao, 1997) and cytokine production in uterine cervical fibroblasts (Sugano et al., 2001) . Indeed, it has been proposed that PAF is an unique biologic regulator with diverse functions (Kume and Shimizu, 1997) .
The functional role (if any) of PAF in the malignant transformation of epithelial cells or in the suppression of their transformed and malignant phenotype is not known. Ectopic expression of the PAF receptor in normal rat kidney mesenchymal fibroblasts, however, has been reported to suppress v-src-or v-ras-induced transformation (Kume and Shimizu, 1997) . We had earlier shown that 1-O(2-methoxy) hexadecyl glycerol, a lipid with similar aliphatic fatty acid chains to that of PAF is biologically active and suppresses the malignant properties of human colon and prostate cancer cells (Wang et al., 1999; Reynolds et al., 2000) . In this study, we showed that PAF-activated MAP kinases, induced a more differentiated phenotype and suppressed the malignant properties of human colon carcinoma cells. Three human colon carcinoma cell lines with different phenotypic properties were selected for this study. These are the moderately differentiated and growth factorresponsive Moser (Huang et al., 1992) , the growth factor-unresponsive and highly tumorigenic HT29 (Huang et al., 1992; Schroy, 1994) and the growth factor-unresponsive and poorly differentiated HCT116 (Brattain et al., 1984; Huang et al., 1992) .
The antiproliferative effect of PAF was investigated in these colon carcinoma cells cultured in medium containing 5% fetal bovine serum. Serum containing medium was used because the lack of serum would induce quiescence and growth arrest in these cells and thus, making it impossible to investigate the antiproliferative effect of PAF. A serial dilution of a PAF (12.5-100 mm) was used to establish a dose-response curve to PAF. PAF at a concentration of 12.5 mm inhibited cell growth that ranged from 40 to 70% by comparison to untreated control cells, and higher concentrations of PAF (50 mm) essentially inhibited the growth of all the cells by as much as 80% (Figure 1a ). PAF-induced growth inhibition was found to be associated with the induction of the cyclin-dependent kinase inhibitor Waf1/p21 (Figure 1b) . Addition of PAF (10 mm) to actively proliferating cells cultured in serum-containing medium induced the Figure 1 Effect of PAF on cellular proliferation, Waf1/p21 expression and the production of CEA. (a) PAF and cellular proliferation. Cellular proliferation was determined by the MTT assay in 96-well culture plates as described previously (Wang et al., 1999) . Briefly, cells were seeded into 96-well culture plates (200 ml per well at a density of 20 000 cells/ml) and allowed to attach overnight. The culture medium was then replenished with fresh medium (controls) or medium containing different concentration of PAF. The cells were cultured for 3 days and the number of cells in each well was estimated by the MTT method. PAF-treated cells were expressed as a percentage of untreated controls and as percent inhibition of growth. Six replicates were performed for each concentration of PAF. Error bars represent the standard error of the mean of five separate experiments. (b) PAF and Waf1/p21 expression. Cells were treated with PAF for 16 h and processed for Western analyses using anti-Waf1/p21 antibodies as described previously (Wang and Chakrabarty, 2001) . Platelet-activating factor in human colon H Wang and S Chakrabarthy elevated expression of Waf1/p21 (Figure 1b) . Since the induction of Waf1/p21 is associated with growth inhibition and the induction of differentiation (Di Cunto et al., 1998; Chakrabarty et al., 1998) , we determined the effect of PAF on CEA production, a differentiationrelated marker for colon carcinomas (Chakrabarty et al., 1988; Guadagni et al., 1990; Reynolds et al., 1998 Reynolds et al., , 2000 Wang et al., 1999) . A one-time treatment of these cells (healthy and actively proliferating) with PAF (5-10 mm) induced a significant increase in CEA production Figure 2 Effect of PAF on anchorage-independent growth and cellular invasion. (a) PAF-and anchorage-independent growth. Growth in soft agarose was performed as described previously (Wang et al., 1999) . Cells were first treated with PAF in culture flasks for 3 days before seeding into soft agarose. Healthy and attached PAF-treated and untreated control cells were detached by trypsinization. A total of 5000 viable cells were seeded into each soft agarose dish (60 Â 15 mm 2 ). The dishes were cultured for 10 days, stained with p-iodonitrotetrazolium violet and the number of colonies manually counted with the aid of a magnifying lens. Each determination was performed in triplicates and the error bars represent the standard error of the mean of three independent experiments. (b) PAF and cellular invasion. This assay was performed as previously described using matrigel-coated invasion chambers (Wang et al., 1999) . Cells were first treated with PAF in culture flasks for 3 days before seeding into the invasion chambers. Healthy and viable PAF-treated and untreated control cells (50 000) were seeded into each rehydrated invasion chambers immersed in NIH3T3 conditioned medium. The chambers were incubated in a humidified incubator at 371C for 4 days. The cells that penetrated to the bottom of the matrigel and the cells that migrated to the bottom chamber were collected, pooled and their number determined by counting with the aid of a hemocytometer. Each determination was performed in triplicates and the error bars represent the standard error of the mean of two independent experiments Platelet-activating factor in human colon H Wang and S Chakrabarthy Figure 3 Activation of MAP kinases by PAF. Human colon carcinoma cell lines Moser, HT29 and HCT116 were cultured as previously described (Wang et al., 1999) . Cells were washed, adapted to serum-free conditions for a couple of hour, and treated with PAF (5 mm) in (a-d), and 50 nm in (f) in serum-free medium for the amount of time as indicated below. Cells were harvested for Western analyses as described previously (Wang and Chakrabarty, 2001 ) using phospho-specific antibodies directed against each of the MAP kinases. (Kunz et al., 1992) . Amplified fragments were analysed by 3% agarose gel electrophoresis and the expected size of the product was 239 bp. Lane 1, positive control U937 cells; lane 2, Moser; lane 3, HT29 and lane 4, HCT116. (f) Western analyses using phospho-specific antibodies to ERKs (p44 and p42) (Figure 1c) . The poorly differentiated HCT116 cells produced the least amount of CEA and responded to PAF (in terms of CEA production) in a dose-dependent manner (Figure 1c) .
Since the induction of differentiation of colon carcinoma cells is associated with a suppression of their malignant phenotype (Reynolds et al., 1998 (Reynolds et al., , 2000 Wang et al., 1999) , we determined the effect of PAF on the malignant properties of these cells. Malignant properties were assessed in terms of the propensity to grow in soft agarose or anchorage-independent growth, and to invade a matrigel matrix or cellular invasion (Reynolds et al., 1998 (Reynolds et al., , 2000 Wang et al., 1999) . These experiments were performed using healthy viable cells in medium containing serum because serum starvation itself would suppress growth in agarose (a 10-day culture period) and cellular invasion (a 4-day culture period). The propensity of healthy and viable PAF-treated cells to grow in soft agarose (Figure 2a ) and to invade a matrigel matrix (Figure 2b ) was found to be significantly reduced by one-time treatment of the cells with 10 and 20 mm PAF, respectively.
Since activation of MAP kinases has been reported in other cell types, we examined the effect of PAF on the activation of three prominent mammalian MAPK modules (Schaeffer and Weber, 1999) . Healthy viable cells cultured in serum-containing medium were washed, and adapted to serum-free conditions for several hours before treatment with PAF. Western blot analyses using phospho-specific antibodies directed against MAP kinases showed that PAF rapidly activated the proliferation and differentiation associated extracellular regulated kinase (ERK) p42 MAPK (Figure 3a) . ERK p42 MAPK was activated in all cell lines within 30 min following the addition of PAF to the culture medium. Activation of p42 MAPK was observed within 15 min following PAF treatment in the HT29 and HCT116 cells, but not in the Moser cells (Figure 3a) . No activation of the closely related ERK p44 MAPK was observed (Figure 3a) . The stress-related p38MAPK was rapidly activated (within 15 min) by PAF in the both the Moser and the HCT116 cells (Figure 3b) . A relatively more sustained activation of p38MAPK was observed in the HCT116 cells (Figure 3b, bottom panel) . Activation of p38MAPK was observed in the HT29 cells after 30 min of exposure to PAF (Figure 3b middle panel) . Next, we determined if C-Jun was activated by the stress-related Jun N-terminal kinases. C-Jun was activated by phosphorylation at Ser 63 in both the HT29 and HCT116 cells with a relatively more sustained activation in the HT29 cells (Figure 3c ). Phosphorylation of C-Jun at Ser 63, however, was not observed in the Moser cells (not shown). On the contrary, C-Jun in the Moser cells was activated by phosphorylation at Ser 73 (Figure 3d) , which was not observed in the HT29 and HCT116 cells (not shown). The use of nonphospho antibodies did not detect changes in the expression of these signal molecules during this short treatment period (15-30 min) with PAF. Thus, we have shown that three prominent MAPK signal modules were rapidly activated by PAF in these phenotypically different colon carcinoma cells and that some heterogeneity was observed in the activation of these signal modules. Immunoblotting and RT-PCR analyses (using U937 cells as positive controls) showed that these colon carcinoma cells expressed the PAF receptor (Figure 3e ). Treatment of these cells with PAF (50 nm) in serum-free conditions rapidly stimulated the ERKs in these cells (Figure 3f) .
Chemoprevention of cancer, that is, the use of chemical agents to prevent, delay or reverse the development of cancer has aroused great interest in recent years. Little is known about the use of this class of agents in the induction of differentiation in vitro or in vivo. Since the induction of differentiation in vitro may be equivalent to chemoprevention in vivo, PAF or PAFlike phospholipids could offer a new class of compounds with potential chemopreventive properties in colon cancer. It is unlikely that the concentrations used in this in vitro study, using a one-time treatment protocol, is achievable in plasma in an in vivo model. Since chemoprevention is a long-term and continuous process, it would be of interest to investigate if the use of nontoxic, low concentrations of PAF, over a long period, could induce differentiation of colon cancer cells in vitro or in vivo in an animal model. In summary, the phospholipid PAF was found to be biologically active in three epithelial-derived human colon carcinoma cell types that expressed the PAF receptor. PAF activated MAP kinases, induced growth inhibition and differentiation and suppressed the malignant properties of these cells. Thus, PAF is a modulator of proliferation and differentiation of epithelial-derived human colon carcinoma cells.
